Hydrazone Modulators for Selective Cannabinoid Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain and other cannabinoid receptor-mediated disorders lack effective solutions, with existing cannabinoid receptor agonists causing CNS side effects and CB2 receptor modulators not fully characterized for functional assays.
Innovation Solution
Development of novel hydrazone compounds that selectively modulate CB1 and CB2 cannabinoid receptors, providing therapeutic compositions and methods for treating neuropathic pain and other disorders by administering these compounds, which are designed to avoid psychoactive effects and optimize receptor modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cannabinoid receptor agonists are used to treat neuropathic pain, then pain relief is achieved, but CNS side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (hydrazone core with particular substituent patterns) that enable selective binding to CB2 receptors while excluding CB1 receptors. This structural differentiation creates localized interaction characteristics that achieve pain relief through CB2 activation without triggering CB1-mediated CNS side effects
Solution Approach 2:
The invention segments the cannabinoid receptor system into distinct CB1 and CB2 targets, then develops compounds that selectively modulate only the CB2 segment. This segmentation approach allows therapeutic action on pain pathways mediated by CB2 while leaving CB1 pathways unaffected, thereby eliminating psychoactive side effects
2Adaptability or versatility
If CB2 receptor modulators are developed to avoid CNS side effects, then selectivity is improved, but functional assay characterization is insufficient
Solution Approach 1:
The patent introduces specific molecular structures as intermediaries that facilitate the measurement and characterization of CB2 selectivity. These structured compounds serve as model systems that enable functional assays to detect and quantify CB2 receptor modulation with high precision, overcoming the previous difficulty in characterizing CB2-selective activity
3Object-affected harmful factors
If hydrazone compounds are designed to selectively modulate CB2 receptors, then psychoactive effects are minimized, but compound complexity increases
Solution Approach 1:
The invention employs parameter changes by systematically varying molecular substituents (R1-R6 groups) on the hydrazone core structure to optimize CB2 selectivity. By adjusting these structural parameters within defined ranges, the compounds achieve high CB2 selectivity and minimal psychoactivity while maintaining reasonable structural complexity through controlled variation rather than complete structural redesign
Data Source
AI summary
Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.